Genetic Testing Organization FHIR Representation: Taiwan NHI Guideline Released
基因檢測機構- XML Representation - 臺灣健保癌症用藥事前審查實作指引v1.0.1 健保署 http://hl7.org/fhir ; org-gene-example ;
The National Health Insurance Administration (NHIA) released guidelines detailing the XML representation of gene testing for pre-approval review of cancer drugs.
Summary
Taiwan's National Health Insurance (NHI) has updated its pre-screening guidelines for cancer drug use, providing the data structure for 'Genetic Testing Organizations' in FHIR format. This aims to ensure consistency and standardization when handling genomic information in clinical settings.
Key Players
Details
The Ministry of Health and Welfare's National Health Insurance Administration (NHI) released the 'Taiwan NHI Cancer Drug Pre-screening Implementation Guide v1.0.1,' providing a data structure for genetic testing organizations based on FHIR (HL7® FHIR® Standard) R4. This guideline is part of the pre-screening process for drug use in cancer treatment, specifically aiming to provide a standardized representation for the entity 'Genetic Testing Organization.' The provided XML reference utilizes the `Organization` resource type and applies a specific profile (Profile: Genetic Testing Organization Genetic Testing TWPAS). This structure includes metadata essential for interoperability in medical information systems, such as institutional codes and system identifiers. The release of this guideline is significant for promoting advanced personalized medicine in Taiwan. By handling complex clinical data, including genomic information, using standard international specifications (FHIR), it ensures interoperability between different systems, contributing to the establishment of a smoother healthcare delivery system. Note that this guide is v1.0.1, and the latest version is stated as 1.2.4.
Technology Note
FHIR（Fast Healthcare Interoperability Resources）は医療データ交換の国際標準。このエントリの関連技術: HL7
Original content copyright by respective publishers